- Innovative Medicine
- Immunology
- Autoantibody diseases
Autoantibody diseases
At Johnson & Johnson, we are relentlessly driven to make a difference in the lives of patients and families impacted by immune-mediated diseases. This commitment includes autoantibody diseases, which are caused by harmful antibodies – also known as autoantibodies – made by one’s own body that attack critical organs and tissues.
Our research has the potential to help the estimated 240 million people worldwide who suffer from autoantibody diseases, many of which have no safe, effective treatments. Johnson & Johnson aims to revolutionize care for patients with a novel therapy that reduces autoantibodies while maintaining immune function, furthering our goal to redefine treatments for immune diseases.
Learn more about autoantibody diseases, which comprise a large and varied group of more than 80 chronic autoimmune and acute alloimmune conditions, that span rare and prevalent diseases including:
Our research has the potential to help the estimated 240 million people worldwide who suffer from autoantibody diseases, many of which have no safe, effective treatments. Johnson & Johnson aims to revolutionize care for patients with a novel therapy that reduces autoantibodies while maintaining immune function, furthering our goal to redefine treatments for immune diseases.
Learn more about autoantibody diseases, which comprise a large and varied group of more than 80 chronic autoimmune and acute alloimmune conditions, that span rare and prevalent diseases including:
Disease areas
Newsroom
See all latest autoantibody news by visiting our newsroom.
Featured resources
Johnson & Johnson’s mission to develop targeted treatments for autoantibody diseases
Read more
You are now leaving jnj.com
This link will take you to a website outside of Johnson and Johnson, which is governed by its own privacy policy and terms of use.
You are now leaving jnj.com
This link will take you to a website outside of Johnson and Johnson, which is governed by its own privacy policy and terms of use.
An investigative treatment with the potential to treat millions of patients: targeting IgG-driven allo- and autoantibody diseases
Read more
You are now leaving jnj.com
This link will take you to a website outside of Johnson and Johnson, which is governed by its own privacy policy and terms of use.
You are now leaving jnj.com
This link will take you to a website outside of Johnson and Johnson, which is governed by its own privacy policy and terms of use.